Abstract
Leukocytosis is a common finding in pediatric patients, and the differential diagnosis can be broad, including benign reactive leukocytosis and malignant myeloproliferative disorders. Transient abnormal myelopoiesis is a myeloproliferative disorder that occurs in young infants with constitutional trisomy 21 and somatic GATA1 mutations. Most patients are observed, but outcomes span the spectrum from spontaneous resolution to life-threatening complications. Juvenile myelomonocytic leukemia is a highly aggressive myeloproliferative disorder associated with altered RAS-pathway signaling that occurs in infants and young children. Treatment typically involves hematopoietic stem cell transplantation, but certain patients can be observed. Early recognition of these and other myeloproliferative disorders is important and requires a clinician to be aware of these diagnoses and have a clear understanding of their presentations. This paper discusses the presentation and evaluation of leukocytosis when myeloproliferative disorders are part of the differential and reviews different concepts regarding treatment strategies.
References
1.
Orkin
SH
, Nathan
DG
, Ginsburg
D
, et al, eds. Nathan and Oski’s Hematology and Oncology of Infancy and Childhood (8th ed)
. Philadelphia, PA
: Elsevier/Saunders
; 2014
.2.
Lanzkowsky
P
, Lipton
JM
, Fish
JD
, eds. Lanzkowsky’s manual of pediatric hematology and oncology (6th ed)
. London
: Academic Press
; 2016
.3.
Hasle
H
, Clemmensen
IH
, Mikkelsen
M.
Risks of leukaemia and solid tumours in individuals with Down's syndrome
. Lancet
. 2000
;355
(9199
):165
-169
. doi:10.1016/s0140-6736(99)05264-2
.4.
Marlow
EC
, Ducore
J
, Kwan
ML
, et al. Leukemia risk in a cohort of 3.9 million children with and without Down Syndrome
. J Pediatr
. 2021
;234
(suppl
): 172
-180.e3180e3
. doi:10.13039/100000054
.5.
Khoury
JD
, Solary
E
, Abla
O
, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms
. Leukemia
. 2022
;36
(7
):1703
-1719
. doi:10.1038/s41375-022-01613-1
.6.
Wechsler
J
, Greene
M
, McDevitt
MA
, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome
. Nat Genet
. 2002
; 32
(1
):148
-152
. doi:10.1038/ng955
.7.
Alford
KA
, Reinhardt
K
, Garnett
C
, et al; International Myeloid Leukemia- Down Syndrome Study Group
. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia
. Blood
. 2011
;118
(8
):2222
-2238
. doi:10.1182/blood-2011-03-342774
.8.
Roberts
I.
Leukemogenesis in infants and young children with trisomy 21
. Hematology
. 2022
;2022
(1
):1
-8
. doi:10.1182/hematology.2022000395
.9.
Roberts
I
, Alford
K
, Hall
G
, et al; Oxford-Imperial Down Syndrome Cohort Study Group
. GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia
. Blood
. 2013
;122
(24
):3908
-3917
. doi:10.1182/blood-2013-07-515148
.10.
Gamis
AS
, Alonzo
TA
, Gerbing
RB
, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971
. Blood
. 2011
; 118
(26
):6752
-6759
; quiz 6996. doi:10.1182/blood-2011-04-350017
.11.
Massey
GV
, Zipursky
A
, Chang
MN
, et al; Children's Oncology Group (COG)
. A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481
. Blood
. 2006
;107
(12
):4606
-4613
. doi:10.1182/blood-2005-06-2448
.12.
Brouwer
N
, Matarraz
S
, Nierkens
S
, et al. Immunophenotypic analysis of acute megakaryoblastic leukemia: a EuroFlow Study
. Cancers (Basel)
. 2022
;14
(6
). doi:10.3390/cancers14061583
.13.
Klusmann
J-H
, Creutzig
U
, Zimmermann
M
, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome
. Blood
. 2008
;111
(6
):2991
-2998
. doi:10.1182/blood-2007-10-118810
.14.
Tunstall
O
, Bhatnagar
N
, James
B
, et al; British Society for Haematology
. Guidelines for the investigation and management of transient leukaemia of Down Syndrome
. Br J Haematol
. 2018
;182
(2
):200
-211
. doi:10.1111/bjh.15390
.15.
Flasinski
M
, Scheibke
K
, Zimmermann
M
, et al. Low-dose cytarabine to prevent myeloid leukemia in children with Down syndrome: TMD Prevention 2007 Study
. Blood Adv
. 2018
;2
(13
):1532
-1540
. doi:10.1182/bloodadvances.2018018945
.16.
Yamato
G
, Deguchi
T
, Terui
K
, et al. Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome
. Leukemia
. 2021
;35
(5
):1480
-1484
. doi:10.1038/s41375-021-01171-y
.17.
Nikolaev
SI
, Santoni
F
, Vannier
A
, et al. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome
. Blood
. 2013
;122
(4
):554
-561
. doi:10.1182/blood-2013-03-491936
.18.
Yoshida
K
, Toki
T
, Okuno
Y
, et al. The landscape of somatic mutations in Down syndrome–related myeloid disorders
. Nat Genet
. 2013
;45
(11
): 1293
-1299
. doi:10.1038/ng.2759
.19.
Hitzler
JK
, Zipursky
A.
Origins of leukaemia in children with Down syndrome
. Nat Rev Cancer
. 2005
;5
(1
):11
-20
. doi:10.1038/nrc1525
.20.
Hasle
H
, Abrahamsson
J
, Arola
M
, et al. Myeloid leukemia in children 4 years or older with Down syndrome often lacks GATA1 mutation and cytogenetics and risk of relapse are more akin to sporadic AML
. Leukemia
. 2008
;22
(7
):1428
-1430
. doi:10.1038/sj.leu.2405060
.21.
Taub
JW
, Berman
JN
, Hitzler
JK
, et al. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 Trial
. Blood
. 2017
;129
(25
):3304
-3313
. doi:10.1182/blood-2017-01-764324
.22.
Hitzler
J
, Alonzo
T
, Gerbing
R
, et al. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 Trial
. Blood
. 2021
;138
(23
):2337
-2346
. doi:10.1182/blood.2021012206
.23.
Taga
T
, Watanabe
T
, Tomizawa
D
, et al. Preserved high probability of overall survival with significant reduction of chemotherapy for myeloid leukemia in down syndrome: a nationwide prospective study in Japan: reduction of chemotherapy for AML with Down syndrome
. Pediatr Blood Cancer
. 2016
;63
(2
):248
-254
. doi:10.1002/pbc.25789
.24.
Raghuram
N
, Nakashima
K
, Ab Rahman
S
, et al. Survival outcomes of children with relapsed or refractory myeloid leukemia associated with Down syndrome
. Blood Adv
. 2023
;bloodadvances.2022009381. doi:10.1182/bloodadvances.2022009381
.25.
Bertrums
EJM
, Zwaan
CM
, Hasegawa
D
, et al. Guideline for management of non-Down syndrome neonates with a myeloproliferative disease on behalf of the I-BFM AML Study Group and EWOG-MDS
. Haematologica
. 2022
;107
(3
):759
-764
. doi:10.3324/haematol.2021.279507
.26.
Huggard
D
, Doherty
DG
, Molloy
EJ
. Immune dysregulation in children with Down syndrome
. Front Pediatr
. 2020
;8
:73
. doi:10.3389/fped.2020.00073
.27.
Hertzberg
L
, Vendramini
E
, Ganmore
I
, et al. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group
. Blood
. 2010
;115
(5
):1006
-1017
. doi:10.1182/blood-2009-08-235408
.28.
Buitenkamp
TD
, Izraeli
S
, Zimmermann
M
, et al. Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group
. Blood
. 2014
;123
(1
):70
-77
. doi:10.1182/blood-2013-06-509463
.29.
Arber
DA
, Orazi
A
, Hasserjian
R
, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
. Blood
. 2016
;127
(20
):2391
-2405
. doi:10.1182/blood-2016-03-643544
.30.
Arber
DA
, Orazi
A
, Hasserjian
RP
, et al. International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data
. Blood
. 2022
;140
(11
):1200
-1228
. doi:10.1182/blood.2022015850
.31.
Niemeyer
CM
, Arico
M
, Basso
G
, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)
. Blood
. 1997
;89
(10
):3534
-3543
. doi:10.1182/blood.2021014689
.32.
Passmore
SJ
, Chessells
JM
, Kempski
H
, Hann
IM
, Brownbill
PA
, Stiller
CA
. Paediatric myelodysplastic syndromes and juvenile myelomonocytic leukaemia in the UK: a population-based study of incidence and survival
. Br J Haematol
. 2003
;121
(5
):758
-767
. doi:10.1046/j.1365-2141.2003.04361.x
.33.
Locatelli
F
, Niemeyer
CM
. How I treat juvenile myelomonocytic leukemia
. Blood
. 2015
;125
(7
):1083
-1090
. doi:10.1182/blood-2014-08-550483
.34.
Loh
ML
. Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia
. Br J Haematol
. 2011
;152
(6
):677
-687
. doi:10.1111/j.1365-2141.2010.08525.x
.35.
Wintering
A
, Dvorak
CC
, Stieglitz
E
, Loh
ML
. Juvenile myelomonocytic leukemia in the molecular era: a clinician's guide to diagnosis, risk stratification, and treatment
. Blood Adv
. 2021
;5
(22
):4783
-4793
. doi:10.1182/bloodadvances.2021005117
.36.
Duncavage
EJ
, Bagg
A
, Hasserjian
RP
, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia
. Blood
. 2022
;140
(21
):2228
-2247
. doi:10.1182/blood.2022015853
.37.
Chao
AK
, Meyer
JA
, Lee
AG
, et al. Fusion driven JMML: a novel CCDC88C-FLT3 fusion responsive to sorafenib identified by RNA sequencing
. Leukemia
. 2020
;34
(2
):662
-666
. doi:10.1038/s41375-019-0549-y
.38.
Schönung
M
, Meyer
J
, Nöllke
P
, et al. International consensus definition of DNA methylation subgroups in juvenile myelomonocytic leukemia
. Clin Cancer Res
. 2021
;27
(1
):158
-168
. doi:10.1158/1078-0432.CCR-20-3184
.39.
Pinkel
D.
Differentiating juvenile myelomonocytic leukemia from infectious disease
. Blood
. 1998
;91
(1
):365
-367
. doi:10.1182/blood.V91.1.365
.40.
Karow
A
, Baumann
I
, Niemeyer
CM
. Morphologic differential diagnosis of juvenile myelomonocytic leukemia–pitfalls apart from viral infection
. J Pediatr Hematol Oncol
. 2009
;31
(5
):380
. doi:10.1097/MPH.0b013e31819ed260
.41.
Behnert
A
, Lee
AG
, Young
EP
, et al. NUP98-NSD1 Driven MDS/MPN in childhood masquerading as JMML
. J Pediatr Hematol Oncol
. 2021
;43
(6
): e808
-e811
. doi:10.1097/MPH.0000000000001913
.42.
Coenen
EA
, Zwaan
CM
, Reinhardt
D
, et al. Pediatric acute myeloid leukemia with t(8;16)(p11;p13), a distinct clinical and biological entity: a collaborative study by the International-Berlin-Frankfurt-Munster AML-study group
. Blood
. 2013
;122
(15
):2704
-2713
. doi:10.1182/blood-2013-02-485524
.43.
Pérez
B
, Mechinaud
F
, Galambrun
C
, et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia
. J Med Genet
. 2010
;47
(10
):686
-691
. doi:10.1136/jmg.2010.076836
.44.
Martinelli
S
, De Luca
A
, Stellacci
E
, et al. Heterozygous germline mutations in the CBL tumor-suppressor gene cause a Noonan syndrome-like phenotype
. Am J Hum Genet
. 2010
;87
(2
):250
-257
. doi:10.1016/j.ajhg.2010.06.015
.45.
Hecht
A
, Meyer
JA
, Behnert
A
, et al. Molecular and phenotypic diversity of CBL-mutated juvenile myelomonocytic leukemia
. Haematologica
. 2022
; 107
(1
):178
-186
. doi:10.3324/haematol.2020.270595
.Copyright © 2023 by The American Society of Hematology
2023
You do not currently have access to this content.
